Parplus Partners’s Pfizer PFE Stock Holding History

Parplus Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-16,592	Closed	-$617K	–	109
2019 Q4	$617K	Buy	+16,592	New	+$591K	0.12%	38

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Parplus Partners's PFE Position: Q1 2020 in Review

Parplus Partners sold out of Pfizer (PFE) in Q1 2020, closing a stake of 16,592 shares — an estimated $617K sold.

Parplus Partners first reported a position in PFE in Q4 2019 and held it in 1 quarter. The position peaked at $617K in Q4 2019. 2,437 funds tracked by Wall St. Rank hold PFE as of Q1 2020.

Parplus Partners reported no remaining Pfizer position as of Q1 2020 after selling out during the quarter.
Parplus Partners sold 16,592 Pfizer shares in Q1 2020, an estimated $617K.
Parplus Partners first reported a position in Pfizer in Q4 2019 and held it in 1 quarter.
Parplus Partners's Pfizer position peaked at $617K in Q4 2019.
2,437 funds tracked by Wall St. Rank held Pfizer as of Q1 2020.

Based on Parplus Partners's 13F filing for Q1 2020, filed 14 May 2020.